To compare the Efficacy of additional Tumor DebulKing Surgery versus chemotherapy alone in recurrent Platinum-sensitive Ovarian cancer | Not Recruiting
To compare the Efficacy of additional Tumor DebulKing Surgery versus chemotherapy alone in recurrent Platinum-sensitive Ovarian cancer
DESKTOP III
Trial Source

Health Conditions
  • Ovarian Cancer
Not Recruiting
Recruitment Status
ISRCTN39361386
Primary Trial ID Number
Summary
The hypothesis H0: "no difference in the survival probability between treatment groups at any time" will be tested against the alternative H1: "difference in survival probability between groups".
Primary Outcome Measures
  • Overall survival (OS) in patients with platinum-sensitive recurrent ovarian cancer with a positive AGO-score randomized to cytoreductive surgery followed by chemotherapy of the physician's choice versus chemotherapy of the physician's choice alone (recommended: platinum combination therapy). Overall survival is defined as the interval between date of randomisation and date of death.
Secondary Outcome Measures
  • 1. Quality of Life at baseline, 6, and 12 months after randomization assessed by EORTC QLQ 30 and FACT NCCN Ovarian Symptom Index (if available in the language of the participating centre).
  • 2. Progression-free-survival in treatment groups. Progression free survival is defined as interval between date of randomisation and 2nd relapse/progression or death (whatever occurs first). Tumor progression is defined as progressive disease according to Response Evaluation Criteria In Solid Tumors (RECIST) or Gynecologic Cancer Intergroup (GCIG) criteria or death without progression or clinical deterioration of performance status with associated signs of disease (e.g. bowel obstruction and non-measurable disease).
  • 3. Rate of complete resection as prognostic factor
  • 4. Complication rate associated with surgery until definitive hospital discharge (Reattendance within 1 week for surgical complications counts as one hospital stay).
  • 5. Exploratory analysis of surgical characteristics and applied chemotherapy
  • 6. Predictive and prognostic value of cancer antigen-125 (CA-125)
Research Question
  • The hypothesis H0: "no difference in the survival probability between treatment groups at any time" will be tested against the alternative H1: "difference in survival probability between groups".
Design Type
Sorry, this information is not available
Ethics Approval
Approval pending as of 25/05/2011
Publications
Sorry, this information is not available
Countries of Recruitment
Germany; United Kingdom
Participant Sex
Female
Participant Age Range
Adult
Participant Type
Patient
Trial Sample Size
408
Participant Inclusion Criteria
  • 1. Patients with first recurrence of platinum sensitive, invasive epithelial ovarian-, fallopian tube- or primary peritoneal cancer of any initial stage
  • 2. Progression-free interval of at least 6 months after end of last platinum-containing therapy, or recurrence within 6 months or later after primary surgery if the patient has not received prior chemotherapy in patients with International Federation of Gynecology and Obstetrics (FIGO) stage I. Non cytostatic maintenance therapy not containing platinum will not be considered for this calculation
  • 3. A positive AGO-score. Obligatory requirements for a positive AGO recurrence score in platinum-sensitive disease: Performance status Eastern Cooperative Oncology Group (ECOG) 0. No residual tumor after primary surgery (if unknown, alternatively primary FIGO stage I / II). If report from 1st surgery is not available contact study chairman who will decide whether inclusion is possible or not. Absence of ascites (cut off < 500 ml: radiological or ultrasound estimation).
  • 4. Women aged more than or equal to 18 years
  • 5. Complete resection of the tumor by median laparotomy seems possible (estimated by an experienced surgeon). Intra-abdominal disease has to be excluded by magetic resonance imaging (MRI) / computerised tomography (CT) if other surgical approaches for isolated extra-abdominal recurrences are planned
  • 6. Patients who have given their signed and written informed consent and their consent to data transmission and -processing
Participant Exclusion Criteria
  • 1. Patients with non-epithelial tumors as well as borderline tumors
  • 2. Patients without recurrence who are scheduled for diagnostic/second-look surgery or debulking surgery after completion of chemotherapy
  • 3. More than one prior chemotherapy
  • 4. Patients with second, third, or later recurrence
  • 5. Patients with second malignancies who have been treated by laparotomy, as well as other neoplasms, if the treatment might interfere with the treatment of relapsed ovarian cancer or if major impact on prognosis is expected
  • 6. Patients with so-called platinum-refractory tumor, i.e. progression during chemotherapy or recurrence within 6 months after end of former first platinum containing therapy
  • 7. Only palliative surgery planned
  • 8. Radiological signs suggesting metastases not accessible to surgical removal (i.e. complete resection is deemed impossible)
  • 9. Any concomitant disease not allowing surgery and / or chemotherapy
  • 10. Any medical history indicating excessive peri-operative risk
  • 11. Any current medication inducing considerable surgical risk (e.g. bleeding: due to oral anticoagulating agents, bevacizumab)
Interventions
DESKTOP III is a surgery based trial and does not involve any Investigational medicinal products (IMPs): Patients will be randomised into one of two treatment groups: Group A: Surgery (with the aim of complete tumour removal) followed by chemotherapy. The extent of surgery in Group A is difficult to estimate beforehand as it depends how much the tumour has spread. However, the aim is complete tumour removal. These tumours can spread into the whole abdominal cavity, the peritoneum, the intestine, the organs of the upper abdomen and also into the lymph nodes. Secondary surgery may therefore include the removal of these affected parts or further actions if it is an extensive tumour. Patients randomised to Group A, will recover from surgery and will receive chemotherapy. After surgery, patients in Group A will receive the normal treatment and care under the attending doctor. Group B: Chemotherapy only. Patients in Group B will have their treatment and care carried out as normal (as if they weren't in the trial) under the medical care of their attending doctor. For Group B patients, if after chemotherapy it is thought that they may still benefit from surgery, this will certainly be possible. Patients will be interviewed 60 days after the start of the treatment and then followed up by a doctor. The follow up process will be quarterly for 2 years, 6 monthly for 5 years and then annually.
Design Details
Sorry, this information is not available
Study Design
Open label prospective randomised multicentre study
Results Reporting
Sorry, this information is not available
Acronym
DESKTOP III
Scientific Title
A randomised multicentre study to compare the Efficacy of additional Tumor DebulKing Surgery versus chemotherapy alone in recurrent Platinum-sensitive Ovarian cancer
Secondary Trial Identifying Number
AGO-OVAR-ID:AGO-OVAR OP.4 (DESKTOP III)
Website
Sorry, this information is not available
Study Funded By
Clinical Trials Awards and Advisory Committee (CTAAC) (UK)
Funder Type
Sorry, this information is not available
Study Sponsored By
AGO Research GmbH (Germany)
Study Also Sponsored By
Sorry, this information is not available
Primary Sponsor Type
Sorry, this information is not available
Secondary Sponsor Type
Sorry, this information is not available
Key Dates

Date of First Enrollment

01 Oct 2011

Recruitment End Date

01 Oct 2014

Trial End Date

01 Oct 2017

Date added to Registry

04 Aug 2011

Last Updated

07 May 2015